According to USP Chapter 795, the labeling of a compounded nonsterile preparation shall include:

While it is helpful to know the indication for which a compounded preparation is used, USP Chapter 795 does not mandate that this information must be included on the label. Indications can vary based on the provider's intent and are not a regulatory requirement for labeling.

Although awareness of potential side effects is important for patient safety, USP Chapter 795 does not require that anticipated side effects be listed on the label of compounded nonsterile preparations. This information is typically provided through patient counseling or separate documentation rather than as a labeling requirement.

The National Drug Code (NDC) number is used for identifying medications in the market but is not applicable to compounded preparations, as they are not typically assigned NDC numbers. Compounded products are often customized and therefore do not fit within the conventional NDC system, making this choice incorrect for USP labeling requirements.